AAPL   322.50 (+1.38%)
FB   230.20 (+0.46%)
GOOGL   1,439.56 (+1.36%)
AMZN   2,431.09 (+0.86%)
NVDA   346.61 (+1.64%)
CGC   21.27 (+6.88%)
BABA   201.17 (+-0.01%)
MU   47.73 (-3.48%)
TSLA   821.23 (+0.12%)
AMD   52.95 (+0.40%)
T   31.50 (-1.10%)
ACB   15.90 (+3.92%)
F   5.93 (-1.66%)
GILD   75.71 (+1.08%)
DIS   118.49 (-2.50%)
NFLX   420.30 (+0.10%)
BAC   25.34 (-2.46%)
BA   153.55 (+2.70%)
AAPL   322.50 (+1.38%)
FB   230.20 (+0.46%)
GOOGL   1,439.56 (+1.36%)
AMZN   2,431.09 (+0.86%)
NVDA   346.61 (+1.64%)
CGC   21.27 (+6.88%)
BABA   201.17 (+-0.01%)
MU   47.73 (-3.48%)
TSLA   821.23 (+0.12%)
AMD   52.95 (+0.40%)
T   31.50 (-1.10%)
ACB   15.90 (+3.92%)
F   5.93 (-1.66%)
GILD   75.71 (+1.08%)
DIS   118.49 (-2.50%)
NFLX   420.30 (+0.10%)
BAC   25.34 (-2.46%)
BA   153.55 (+2.70%)
AAPL   322.50 (+1.38%)
FB   230.20 (+0.46%)
GOOGL   1,439.56 (+1.36%)
AMZN   2,431.09 (+0.86%)
NVDA   346.61 (+1.64%)
CGC   21.27 (+6.88%)
BABA   201.17 (+-0.01%)
MU   47.73 (-3.48%)
TSLA   821.23 (+0.12%)
AMD   52.95 (+0.40%)
T   31.50 (-1.10%)
ACB   15.90 (+3.92%)
F   5.93 (-1.66%)
GILD   75.71 (+1.08%)
DIS   118.49 (-2.50%)
NFLX   420.30 (+0.10%)
BAC   25.34 (-2.46%)
BA   153.55 (+2.70%)
AAPL   322.50 (+1.38%)
FB   230.20 (+0.46%)
GOOGL   1,439.56 (+1.36%)
AMZN   2,431.09 (+0.86%)
NVDA   346.61 (+1.64%)
CGC   21.27 (+6.88%)
BABA   201.17 (+-0.01%)
MU   47.73 (-3.48%)
TSLA   821.23 (+0.12%)
AMD   52.95 (+0.40%)
T   31.50 (-1.10%)
ACB   15.90 (+3.92%)
F   5.93 (-1.66%)
GILD   75.71 (+1.08%)
DIS   118.49 (-2.50%)
NFLX   420.30 (+0.10%)
BAC   25.34 (-2.46%)
BA   153.55 (+2.70%)
Log in

NASDAQ:CCXIChemoCentryx Stock Price, Forecast & News

$61.24
-1.90 (-3.01 %)
(As of 05/28/2020 01:59 PM ET)
Add
Compare
Today's Range
$60.71
Now: $61.24
$63.75
50-Day Range
$42.60
MA: $51.94
$60.27
52-Week Range
$6.16
Now: $61.24
$63.46
Volume26,913 shs
Average Volume621,328 shs
Market Capitalization$3.79 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.08
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis; and Phase IIb clinical trial, the AURORA trial for the treatment of patients with moderate-to-severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy and is being developed for patients with focal segmental glomerulosclerosis; CCX507, a second generation CCR9 inhibitor, which has completed Phase I clinical trial; and CCX872, a potent and selective inhibitor of CCR2, which is in phase Ib clinical trial for the treatment of patients with stage 3 and 4 pancreatic cancer. ChemoCentryx, Inc. was founded in 1996 and is headquartered in Mountain View, California.
Read More
ChemoCentryx logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.6Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.45 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CCXI
CUSIP16383L10
Phone650-210-2900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$36.13 million
Book Value$0.97 per share

Profitability

Net Income$-55,490,000.00
Net Margins-192.93%

Miscellaneous

Employees82
Market Cap$3.79 billion
Next Earnings Date8/3/2020 (Estimated)
OptionableOptionable

Receive CCXI News and Ratings via Email

Sign-up to receive the latest news and ratings for CCXI and its competitors with MarketBeat's FREE daily newsletter.

ChemoCentryx (NASDAQ:CCXI) Frequently Asked Questions

How has ChemoCentryx's stock been impacted by COVID-19 (Coronavirus)?

ChemoCentryx's stock was trading at $41.54 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CCXI stock has increased by 47.4% and is now trading at $61.24. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of ChemoCentryx?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ChemoCentryx in the last year. There are currently 7 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ChemoCentryx.

When is ChemoCentryx's next earnings date?

ChemoCentryx is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for ChemoCentryx.

How were ChemoCentryx's earnings last quarter?

ChemoCentryx Inc (NASDAQ:CCXI) posted its quarterly earnings data on Monday, May, 11th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by $0.05. The biopharmaceutical company had revenue of $6.01 million for the quarter, compared to analysts' expectations of $8.90 million. ChemoCentryx had a negative return on equity of 100.55% and a negative net margin of 192.93%. View ChemoCentryx's earnings history.

What price target have analysts set for CCXI?

8 brokerages have issued 12-month price targets for ChemoCentryx's stock. Their forecasts range from $54.00 to $102.00. On average, they anticipate ChemoCentryx's stock price to reach $70.13 in the next twelve months. This suggests a possible upside of 14.5% from the stock's current price. View analysts' price targets for ChemoCentryx.

Has ChemoCentryx been receiving favorable news coverage?

Media stories about CCXI stock have trended very positive this week, InfoTrie Sentiment reports. The research group rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ChemoCentryx earned a news impact score of 3.1 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the immediate future. View the latest news aboutChemoCentryx.

Are investors shorting ChemoCentryx?

ChemoCentryx saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 2,060,000 shares, a decline of 18.3% from the April 30th total of 2,520,000 shares. Based on an average trading volume of 627,400 shares, the short-interest ratio is currently 3.3 days. Approximately 4.7% of the company's stock are sold short. View ChemoCentryx's Current Options Chain.

Who are some of ChemoCentryx's key competitors?

What other stocks do shareholders of ChemoCentryx own?

Who are ChemoCentryx's key executives?

ChemoCentryx's management team includes the following people:
  • Dr. Thomas J. Schall Ph.D., Founder, Pres, CEO & Chairman (Age 61, Pay $968.76k)
  • Ms. Susan M. Kanaya, Exec. VP, Chief Financial & Admin. Officer and Sec. (Age 57, Pay $696.65k)
  • Dr. Markus J. Cappel, Sr. VP, Chief Bus. Officer & Treasurer (Age 59, Pay $563.8k)
  • Ms. Kari E. Leetch, Sr. VP of HR
  • Dr. Catherine Lee Kelleher, Sr. VP of Clinical Devel.

What is ChemoCentryx's stock symbol?

ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."

Who are ChemoCentryx's major shareholders?

ChemoCentryx's stock is owned by many different retail and institutional investors. Top institutional shareholders include RA Capital Management L.P. (6.75%), BlackRock Inc. (6.33%), Wasatch Advisors Inc. (1.94%), State Street Corp (1.74%), UBS Group AG (1.46%) and Pictet Asset Management Ltd. (1.23%). Company insiders that own ChemoCentryx stock include Geoffrey M Parker, James L Tyree, Markus J Cappel, Plc Glaxosmithkline, Pui San Kwan, Rajinder Singh, Susan M Kanaya and Thomas J Schall. View institutional ownership trends for ChemoCentryx.

Which major investors are selling ChemoCentryx stock?

CCXI stock was sold by a variety of institutional investors in the last quarter, including Sofinnova Investments Inc., BlackRock Inc., Acadian Asset Management LLC, Frontier Capital Management Co. LLC, Wasatch Advisors Inc., WINTON GROUP Ltd, Morgan Stanley, and Two Sigma Advisers LP. Company insiders that have sold ChemoCentryx company stock in the last year include Geoffrey M Parker, James L Tyree, Markus J Cappel, Pui San Kwan, Susan M Kanaya, and Thomas J Schall. View insider buying and selling activity for ChemoCentryx.

Which major investors are buying ChemoCentryx stock?

CCXI stock was bought by a variety of institutional investors in the last quarter, including RA Capital Management L.P., Pictet Asset Management Ltd., Lord Abbett & CO. LLC, Emerald Advisers LLC, International Biotechnology Trust PLC, Canada Pension Plan Investment Board, Emerald Mutual Fund Advisers Trust, and Invesco Ltd.. View insider buying and selling activity for ChemoCentryx.

How do I buy shares of ChemoCentryx?

Shares of CCXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ChemoCentryx's stock price today?

One share of CCXI stock can currently be purchased for approximately $61.24.

How big of a company is ChemoCentryx?

ChemoCentryx has a market capitalization of $3.79 billion and generates $36.13 million in revenue each year. The biopharmaceutical company earns $-55,490,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. ChemoCentryx employs 82 workers across the globe.

What is ChemoCentryx's official website?

The official website for ChemoCentryx is www.chemocentryx.com.

How can I contact ChemoCentryx?

ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The biopharmaceutical company can be reached via phone at 650-210-2900 or via email at [email protected]

This page was last updated on 5/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.